NCT06490432

Brief Summary

Study the relationship between patients with MASLD and cardiac arrhythmia that could be occur in thos patients

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 8, 2024

Completed
18 days until next milestone

Study Start

First participant enrolled

July 26, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 20, 2025

Completed
Last Updated

August 7, 2024

Status Verified

August 1, 2024

Enrollment Period

11 months

First QC Date

June 30, 2024

Last Update Submit

August 6, 2024

Conditions

Cardiac ArrhythmiaMetabolic Dysfunction Associated Steatotic Liver Disease

Outcome Measures

Primary Outcomes (2)

  • Cardiac arrhythmia and MASLD patients

    Study metabolic dysfunction -assocatied steatotic liver disease

    1 year

  • Cardiac arrhythmia

    Study pattern of cardiac arrhythmia

    1 year

Interventions

Transient elastographyDEVICE

Device that measures stiffness of liver tissue

Also known as: Echocardiograpy, ECG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Study relationship between patients with metabolic dysfunction -assocatied steatotic liver disease and cardiac arrhythmia in those patients

You may qualify if:

  • patients aged 18years or older Patients with metabolic dysfunction -assocatied steatotic liver disease

You may not qualify if:

  • RHD Structural heart diseases Liver diseases other than MASLD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University Hospital

Sohag, So, Egypt

RECRUITING

Related Publications (1)

  • Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024 Feb 23;73(3):533-540. doi: 10.1136/gutjnl-2023-331003.

    PMID: 37907259BACKGROUND

MeSH Terms

Conditions

Arrhythmias, Cardiac

Interventions

Electrocardiography

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Study Officials

  • Mohamed Ahmed Mostafa, Lecturer

    Sohag University

    STUDY DIRECTOR

Central Study Contacts

Asmaa Rashwan Ahmed, doctor

CONTACT

01118523043asmarshwan5@gmail.com

Usama Mohamed Abdalaal, Professor

CONTACT

+20 106 596 2094

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

June 30, 2024

First Posted

July 8, 2024

Study Start

July 26, 2024

Primary Completion

July 1, 2025

Study Completion

October 20, 2025

Last Updated

August 7, 2024

Record last verified: 2024-08

Locations

EG(1)